SS-31 (Elamipretide)
SS-31, also known as Elamipretide or Bendavia, is a small aromatic-cationic tetrapeptide that selectively targets mitochondria.
Also known as: Mitochondrial-Targeted Peptide, Cardiolipin Protector, Elamipretide
Overview
SS-31, also known as Elamipretide or Bendavia, is a small aromatic-cationic tetrapeptide that selectively targets mitochondria. Unlike traditional antioxidants, SS-31 specifically binds to cardiolipin in the inner mitochondrial membrane, protecting it from oxidative damage and improving cellular energy production. This unique mechanism makes it particularly promising for age-related conditions, heart disease, and mitochondrial disorders.
Key Benefits
- Enhanced ATP Production
- Oxidative Stress Reduction
- Mitochondrial Disease Support
Directly protects mitochondria, improves cellular energy, reduces oxidative damage, enhances exercise capacity
Mechanism of Action
Selectively binds to cardiolipin in inner mitochondrial membrane, preventing lipid peroxidation and optimizing electron transport chain function
Pharmacokinetics
Peak plasma concentration: 30 min. Elimination half-life: 4 hrs. Largely cleared by: ~20 hrs.
Research Protocols Injectable
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General Mitochondrial Support | 5-10mg | Once daily | Subcutaneous |
| Athletic Performance | 10-20mg | Once daily pre-workout | Subcutaneous |
| Clinical Protocols | 40mg | Once daily | Subcutaneous |
| Acute Cardioprotection | 0.25mg/kg/hr | Continuous infusion | Subcutaneous |
Research protocols from published literature — not dosing recommendations.
Peptide Interactions
- NAD+ — Synergistic: Both support mitochondrial function through different mechanisms - SS-31 protects membranes while NAD+ enhances energy production
- MOTS-c — Synergistic: Both are mitochondrial peptides - MOTS-c regulates metabolism while SS-31 protects mitochondrial structure
- Humanin — Synergistic: Another mitochondrial-derived peptide - may work together to protect cellular function and reduce apoptosis
- GHK-Cu — Compatible: Different mechanisms - GHK-Cu works on gene expression while SS-31 directly protects mitochondria
- BPC-157 — Compatible: No known interactions - BPC-157 focuses on tissue repair while SS-31 targets cellular energetics
- Thymosin Beta-4 — Compatible: Both have cardioprotective effects through different pathways - may be complementary
Peptide Instructions Injectable
Supplies:
- SS-31 (Elamipretide) peptide vial
- Bacteriostatic water or saline
- Insulin syringes (for SubQ)
- Alcohol prep pads
- Sterile filter (optional for IV use)
How to Reconstitute Injectable
- 1Clean vial top with alcohol pad
- 2Add appropriate amount of bacteriostatic water (typically 1-2mL per 10mg)
- 3Gently swirl to dissolve - SS-31 dissolves readily
- 4Solution should be clear and colorless
- 5For IV use, may require sterile filtration
- 6Label with concentration and date
- 7Store in refrigerator immediately
What to Expect Injectable
Day 1-3: Subtle energy improvements, reduced fatigue. Week 1-2: Better exercise endurance, faster recovery. Week 2-4: Improved stamina, clearer thinking, better sleep quality. Week 4-8: Significant improvements in exercise capacity. Week 8-12: Sustained energy improvements, potential biomarker changes.
Side Effects & Safety
Excellent safety profile in clinical trials. No significant side effects reported at therapeutic doses. May cause mild injection site reactions. Monitor for allergic reactions (very rare). Safe for long-term use based on current data. No known drug interactions.
Excellent safety profile in clinical trials. No significant side effects reported at therapeutic doses. May cause mild injection site reactions. Monitor for allergic reactions (very rare). Safe for long-term use based on current data. No known drug interactions.
Community Insights
SS-31 (Elamipretide) should be stored at Refrigerate after reconstitution, protect from light, use within 30 days.
References
- Barth Syndrome Clinical Trial - FDA Approval (2025)
- Age-Related Muscle Dysfunction Study (2020)
- Cardioprotection in Heart Failure Model (2019)
- Phase 2 Trial for Primary Mitochondrial Myopathy (2018)
Research reference only. Not medical advice.